Inhibikase Therapeutics
IKT
13 hedge funds and large institutions have $598K invested in Inhibikase Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
5.63% more ownership
Funds ownership: 2.41% → 8.03% (+5.6%)
7% less funds holding
Funds holding: 14 → 13 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
78% less capital invested
Capital invested by funds: $2.69M → $598K (-$2.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$31K |
| 2 |
Renaissance Technologies
New York
|
+$7.62K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$3.33K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$484 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$334 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$696K |
| 2 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$49.8K |
| 3 |
Barclays
London,
United Kingdom
|
-$41.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.93K |
| 5 |
Edgewood Management
Greenwich,
Connecticut
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $259K | -$696K | -310,501 | -63% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $122K | -$1.93K | -863 | -1% |
|
|
3
William Blair & Company
Chicago,
Illinois
| $82.5K | +$3.33K | +1,487 | +3% |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $40.5K | +$31K | +13,852 | +93% |
|
|
RAM
5
Redmond Asset Management
Henrico,
Virginia
| $29.2K | +$2 | +1 | +0% |
|
|
6
Edgewood Management
Greenwich,
Connecticut
| $23.2K | -$2 | -1 | -0% |
|
|
7
Renaissance Technologies
New York
| $22K | +$7.62K | +3,400 | +27% |
|
8
State Street
Boston,
Massachusetts
| $14.2K | +$4 | +2 | +0% |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $3.06K | +$484 | +216 | +11% |
|
10
Morgan Stanley
New York
| $2.32K | – | – | – |
|
11
Wells Fargo
San Francisco,
California
| $322 | +$81 | +36 | +18% |
|
|
12
UBS Group
Zurich,
Switzerland
| $207 | +$334 | +149 | New |
|
13
JP Morgan Chase
New York
| $7 | +$7 | +3 | +150% |
|
|
HLA
14
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$49.8K | -13,802 | Closed |
|
|
15
Barclays
London,
United Kingdom
| – | -$41.4K | -11,455 | Closed |
|
IKT Hedge Fund Activity: Q3 2023 in Review
13 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q3 2023, worth a combined $598K — down 78% from $2.69M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IKT and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $31K. The largest seller was Armistice Capital, cutting an estimated $696K.
- 13 institutional investors held Inhibikase Therapeutics (IKT) as of Q3 2023, down from 14 in Q2 2023.
- Funds reported $598K of Inhibikase Therapeutics stock for Q3 2023, down 78% quarter-over-quarter.
- 1 fund opened new Inhibikase Therapeutics positions in Q3 2023 and 2 closed out, a net change of -1 holder.
- The largest Inhibikase Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $31K added.
- The largest Inhibikase Therapeutics seller in Q3 2023 was Armistice Capital, an estimated $696K sold.
Based on aggregated 13F filings for Q3 2023.